TY  - JOUR
AU  - Rubinski, Anna
AU  - Franzmeier, Nicolai
AU  - Neitzel, Julia
AU  - Ewers, Michael
TI  - FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels.
JO  - Alzheimer's research & therapy
VL  - 12
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2021-00113
SP  - 133
PY  - 2020
N1  - ISSN 1758-9193 not unique: **3 hits**.
AB  - FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer's diseases (AD) including amyloid and tau is unclear.Using voxel-based regression, we assessed local interactions between amyloid- and tau-PET on spatially matched FDG-PET in 72 MCI patients. Control groups included cerebrospinal fluid biomarker characterized cognitively normal (CN, n = 70) and AD dementia subjects (n = 95).In MCI, significant amyloid-PET by tau-PET interactions were found in frontal, lateral temporal, and posterior parietal regions, where higher local tau-PET was associated with higher spatially corresponding FDG-PET at low levels of local amyloid-PET. FDG-PET in brain regions with a significant local amyloid- by tau-PET interaction was higher compared to that in CN and AD dementia and associated with lower episodic memory.Higher tau-PET in the presence of low amyloid-PET is associated with abnormally increased glucose metabolism that is accompanied by episodic memory impairment.
KW  - Alzheimer Disease: diagnostic imaging
KW  - Amyloid
KW  - Amyloid beta-Peptides
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Fluorodeoxyglucose F18
KW  - Humans
KW  - Positron-Emission Tomography
KW  - tau Proteins
KW  - Amyloid-PET (Other)
KW  - FDG-PET (Other)
KW  - Hyperactivation (Other)
KW  - Hypermetabolism (Other)
KW  - Mild cognitive impairment (Other)
KW  - Tau-PET (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33076977
C2  - pmc:PMC7574434
DO  - DOI:10.1186/s13195-020-00702-6
UR  - https://pub.dzne.de/record/154259
ER  -